David Dai
Stock Analyst at Bernstein
(2.00)
# 2,988
Out of 5,127 analysts
32
Total ratings
41.38%
Success rate
-4.59%
Average return
Main Sectors:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASML ASML Holding | Maintains: Outperform | $1,528 → $1,642 | $1,413.62 | +16.16% | 2 | Jan 22, 2026 | |
| SONY Sony Group | Maintains: Outperform | $33 → $30 | $22.83 | +31.41% | 1 | Jan 14, 2026 | |
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $4.74 | +47.68% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $7.84 | +104.08% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $108.93 | +7.41% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $21.32 | +78.24% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $102.15 | +29.22% | 3 | Oct 31, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $7.24 | +176.24% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $16.45 | +58.05% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $15.25 | +96.72% | 1 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $2 | $2.60 | -23.08% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $12.19 | +96.88% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $32.77 | -26.76% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $13.13 | +425.51% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $33.25 | +50.38% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $53.09 | +13.02% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $448 | $7.13 | +6,183.31% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $83.30 | -51.98% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.72 | +2,225.58% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $2.00 | +2,400.00% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $28.35 | +83.42% | 1 | Mar 17, 2020 |
ASML Holding
Jan 22, 2026
Maintains: Outperform
Price Target: $1,528 → $1,642
Current: $1,413.62
Upside: +16.16%
Sony Group
Jan 14, 2026
Maintains: Outperform
Price Target: $33 → $30
Current: $22.83
Upside: +31.41%
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $4.74
Upside: +47.68%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $7.84
Upside: +104.08%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $108.93
Upside: +7.41%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $21.32
Upside: +78.24%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $102.15
Upside: +29.22%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $7.24
Upside: +176.24%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $16.45
Upside: +58.05%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $15.25
Upside: +96.72%
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.60
Upside: -23.08%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $12.19
Upside: +96.88%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $32.77
Upside: -26.76%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $13.13
Upside: +425.51%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $33.25
Upside: +50.38%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $53.09
Upside: +13.02%
Mar 31, 2022
Initiates: Outperform
Price Target: $448
Current: $7.13
Upside: +6,183.31%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $83.30
Upside: -51.98%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.72
Upside: +2,225.58%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $2.00
Upside: +2,400.00%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $28.35
Upside: +83.42%